Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors

Next Previous
Trial Profile

First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELI 002 (Primary)
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Neuroblastoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic ductal carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms AMPLIFY-201; The novel study
  • Sponsors Elicio Therapeutics

Most Recent Events

  • 12 Dec 2024 Results presented in the Elicio Therapeutics Media Release.
  • 12 Dec 2024 According to an Elicio Therapeutics media release, presented updated results from the Phase 1 AMPLIFY-201 clinical trial of ELI-002, an Amphiphile (AMP) cancer vaccine that targets KRAS-mutant tumors, at the ESMO Immuno-Oncology Congress 2024 in Geneva, Switzerland.
  • 13 Nov 2024 According to an Elicio Therapeutics media release, the updated relapse-free survival and overall survival data from this study will be presented in an oral presentation at the 2024 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress, taking place from December 11-13, 2024, in Geneva, Switzerland.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top